MX2012008638A - Metodos de tratamiento de diabetes con antagonistas de ligando tipo delta 4. - Google Patents

Metodos de tratamiento de diabetes con antagonistas de ligando tipo delta 4.

Info

Publication number
MX2012008638A
MX2012008638A MX2012008638A MX2012008638A MX2012008638A MX 2012008638 A MX2012008638 A MX 2012008638A MX 2012008638 A MX2012008638 A MX 2012008638A MX 2012008638 A MX2012008638 A MX 2012008638A MX 2012008638 A MX2012008638 A MX 2012008638A
Authority
MX
Mexico
Prior art keywords
dll4
antagonists
block
antibodies
dll4 antagonists
Prior art date
Application number
MX2012008638A
Other languages
English (en)
Other versions
MX343555B (es
Inventor
Dimitris Skokos
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2012008638A publication Critical patent/MX2012008638A/es
Publication of MX343555B publication Critical patent/MX343555B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención provee métodos para prevenir, tratar o mitigar diabetes al administrar a un sujeto que necesita el mismo una cantidad terapéuticamente efectiva de antagonistas de D114 que bloquean las vías de señal de D114 - Notch. Como se observa en un modelo de diabetes en ratón, los antagonistas de D114 presentan efectos protectores sobre islotes pancreáticos, reducen los niveles de glucosa en la sangre, y bloquean la producción de auto-anticuerpos, incluyendo aquellos contra insulina y ácido glutámico descarboxilasa 65 (GAD65), mediante la expansión de células T reguladoras (Tregs). Por lo tanto, la presente invención además provee métodos para reducir los niveles de glucosa en la sangre, y/o reducir o bloquear la producción de auto-anticuerpos, al administrar a un sujeto que necesita el mismo una cantidad terapéuticamente efectiva de antagonistas de D114. Los antagonistas de D114 adecuados para la invención incluyen anticuerpos o fragmentos de anticuerpo que se unen específicamente a D114 y bloquean las interacciones D114 - Notch, el dominio extracelular de D114, y similares.
MX2012008638A 2010-01-29 2011-01-28 Métodos de tratamiento de diabetes con antagonistas de ligando tipo delta 4. MX343555B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29980110P 2010-01-29 2010-01-29
US36168710P 2010-07-06 2010-07-06
US38869710P 2010-10-01 2010-10-01
PCT/US2011/022817 WO2011094467A2 (en) 2010-01-29 2011-01-28 Methods of treating diabetes with dll4 antagonists

Publications (2)

Publication Number Publication Date
MX2012008638A true MX2012008638A (es) 2012-12-05
MX343555B MX343555B (es) 2016-11-10

Family

ID=43925413

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012008740A MX343553B (es) 2010-01-29 2011-01-28 Métodos de tratamiento de enfermedades autoinmunes con antagonistas de ligando tipo delta 4.
MX2012008638A MX343555B (es) 2010-01-29 2011-01-28 Métodos de tratamiento de diabetes con antagonistas de ligando tipo delta 4.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2012008740A MX343553B (es) 2010-01-29 2011-01-28 Métodos de tratamiento de enfermedades autoinmunes con antagonistas de ligando tipo delta 4.

Country Status (29)

Country Link
US (3) US8765125B2 (es)
EP (2) EP2528946B1 (es)
JP (2) JP5997613B2 (es)
KR (2) KR101832118B1 (es)
CN (2) CN102884081A (es)
AR (1) AR080026A1 (es)
AU (2) AU2011210773B2 (es)
BR (2) BR112012018766A2 (es)
CA (2) CA2787615C (es)
CY (2) CY1118223T1 (es)
DK (2) DK2528945T3 (es)
ES (2) ES2605430T3 (es)
HR (2) HRP20170130T1 (es)
HU (2) HUE032985T2 (es)
IL (2) IL220887A (es)
JO (2) JO3183B1 (es)
LT (2) LT2528945T (es)
MX (2) MX343553B (es)
MY (2) MY156538A (es)
PL (2) PL2528946T3 (es)
PT (2) PT2528945T (es)
RS (2) RS55595B1 (es)
RU (2) RU2587620C2 (es)
SG (4) SG10201500416RA (es)
SI (2) SI2528945T1 (es)
SM (2) SMT201600412B (es)
TW (2) TWI564019B (es)
UY (1) UY33206A (es)
WO (2) WO2011094465A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
EP3029070A1 (en) 2009-08-29 2016-06-08 AbbVie Inc. Therapeutic dll4 binding proteins
ES2895226T3 (es) 2009-10-16 2022-02-18 Mereo Biopharma 5 Inc Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensivos
JO3183B1 (ar) 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
MY160628A (en) 2010-03-02 2017-03-15 Abbvie Inc Therapeutic DLL4 Binding Proteins
BR112014007035B1 (pt) 2011-09-23 2021-05-04 Oncomed Pharmaceuticals, Inc anticorpos biespecíficos que se ligam a vegf/dll4, composição farmacêutica e célula procariótica, fúngica ou de levedura que compreende os mesmos, moléculas de polinucleotídeo, vetor, usos terapêuticos e método para a produção de um anticorpo
KR101535341B1 (ko) * 2012-07-02 2015-07-13 한화케미칼 주식회사 Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도
KR20210111353A (ko) 2012-11-01 2021-09-10 애브비 인코포레이티드 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
TW201438736A (zh) * 2012-11-14 2014-10-16 Regeneron Pharma 以ｄｌｌ４拮抗劑治療卵巢癌之方法
EP3020731B1 (en) 2013-07-09 2019-06-12 ABLBio Novel dual-targeted protein specifically binding to dll4 and vegf, and use thereof
CN111239415B (zh) * 2013-10-17 2024-03-26 综合医院公司 鉴定响应于用于自身免疫性疾病的治疗的受试者的方法以及用于治疗该疾病的组合物
WO2015154795A1 (en) * 2014-04-08 2015-10-15 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Combination therapy for the treatment of autoimmune diseases
DK3212233T3 (da) 2014-10-31 2020-07-27 Oncomed Pharm Inc Kombinationsterapi til behandling af sygdom
AU2016326609B2 (en) 2015-09-23 2023-03-09 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
EP3886856A4 (en) * 2018-11-29 2022-01-19 Zucco Sassi Yonezawa Siviglia, Debora METHOD FOR TREATING OR PREVENTING SEIZURES ASSOCIATED WITH AN EPILEPTIC DISORDER
US11446262B2 (en) 2018-11-29 2022-09-20 Debora Zucco Sassi Yonezawa Siviglia Neuroquiescence—a treatment for neurodevelopmental and neurodegenerative bioelectrical dysregulation and demyelination
WO2022210802A1 (ja) * 2021-03-30 2022-10-06 国立大学法人熊本大学 筋萎縮症治療剤
WO2023159166A1 (en) * 2022-02-18 2023-08-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. Single-domain antibodies (nanobodies) targeting the notch ligand dll4 and methods of their use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
BR0311161A (pt) * 2002-05-21 2005-03-29 Cv Therapeutics Inc Método de tratamento de diabetes
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
US20060134121A1 (en) 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
AU2006326417B2 (en) * 2005-12-16 2012-05-24 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with Dll4 antagonists
CN102585002A (zh) 2006-06-02 2012-07-18 瑞泽恩制药公司 人il-6受体的高亲和力抗体
KR20090027227A (ko) * 2006-06-06 2009-03-16 제넨테크, 인크. 항-ｄｌｌ4 항체 및 이의 사용 방법
WO2007143689A2 (en) 2006-06-06 2007-12-13 Genentech, Inc. Compositions and methods for modulating vascular development
WO2008019144A2 (en) 2006-08-07 2008-02-14 Regeneron Pharmaceuticals, Inc. Threapeutic methods for treating vascular eye disorders with dll4 antagonists
MX2009003229A (es) 2006-09-29 2009-06-18 Oncomed Pharm Inc Composiciones y metodos para diagnosticar y tratar cancer.
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
EP3029070A1 (en) 2009-08-29 2016-06-08 AbbVie Inc. Therapeutic dll4 binding proteins
JO3183B1 (ar) * 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4

Also Published As

Publication number Publication date
MX343555B (es) 2016-11-10
JO3242B1 (ar) 2018-03-08
RS55715B1 (sr) 2017-07-31
DK2528946T3 (en) 2017-02-20
US20110189176A1 (en) 2011-08-04
PL2528946T3 (pl) 2017-04-28
ES2605430T3 (es) 2017-03-14
AU2011210773A1 (en) 2012-08-23
JP2013518123A (ja) 2013-05-20
WO2011094467A3 (en) 2011-12-22
EP2528945B1 (en) 2016-10-26
SI2528946T1 (sl) 2017-01-31
US8889133B2 (en) 2014-11-18
CN102884081A (zh) 2013-01-16
HRP20170130T1 (hr) 2017-03-24
SI2528945T1 (sl) 2017-01-31
AU2011210771A1 (en) 2012-08-23
MX343553B (es) 2016-11-10
IL220889A (en) 2017-07-31
RS55595B1 (sr) 2017-06-30
US20140255429A1 (en) 2014-09-11
CA2787615C (en) 2019-01-15
TW201615207A (zh) 2016-05-01
ES2609663T3 (es) 2017-04-21
KR101797918B1 (ko) 2017-11-15
CY1118551T1 (el) 2017-07-12
RU2587624C2 (ru) 2016-06-20
MX2012008740A (es) 2012-08-31
KR101832118B1 (ko) 2018-02-26
TWI564019B (zh) 2017-01-01
EP2528945A2 (en) 2012-12-05
PL2528945T3 (pl) 2017-02-28
EP2528946B1 (en) 2016-11-16
CN102947336B (zh) 2015-12-02
SG10201500404QA (en) 2015-03-30
AU2011210773B2 (en) 2015-11-19
UY33206A (es) 2011-08-31
SG10201500416RA (en) 2015-04-29
WO2011094465A1 (en) 2011-08-04
LT2528946T (lt) 2017-01-25
IL220889A0 (en) 2012-09-24
KR20130008017A (ko) 2013-01-21
PT2528946T (pt) 2016-12-14
EP2528946A1 (en) 2012-12-05
MY156353A (en) 2016-02-15
SMT201700021B (it) 2017-03-08
TW201136601A (en) 2011-11-01
HRP20170249T1 (hr) 2017-04-07
SG182528A1 (en) 2012-08-30
HUE032985T2 (en) 2017-11-28
CN102947336A (zh) 2013-02-27
CA2787394C (en) 2019-01-08
IL220887A (en) 2017-07-31
RU2012136816A (ru) 2014-03-10
JP2013518122A (ja) 2013-05-20
SMT201600412B (it) 2017-01-10
DK2528945T3 (en) 2017-02-06
KR20120123745A (ko) 2012-11-09
SG182527A1 (en) 2012-08-30
CY1118223T1 (el) 2017-06-28
CA2787615A1 (en) 2011-08-04
RU2587620C2 (ru) 2016-06-20
BR112012018820A2 (pt) 2017-01-10
CA2787394A1 (en) 2011-08-04
US20110189200A1 (en) 2011-08-04
LT2528945T (lt) 2017-01-25
JP5883801B2 (ja) 2016-03-15
AU2011210771B2 (en) 2015-12-10
MY156538A (en) 2016-02-26
JP5997613B2 (ja) 2016-09-28
BR112012018766A2 (pt) 2017-01-10
TWI600433B (zh) 2017-10-01
BR112012018820A8 (pt) 2018-03-13
PT2528945T (pt) 2016-12-14
US8765125B2 (en) 2014-07-01
JO3183B1 (ar) 2018-03-08
RU2012136817A (ru) 2014-03-10
WO2011094467A2 (en) 2011-08-04
AR080026A1 (es) 2012-03-07
WO2011094465A4 (en) 2011-09-22
HUE031432T2 (en) 2017-07-28

Similar Documents

Publication Publication Date Title
MX2012008638A (es) Metodos de tratamiento de diabetes con antagonistas de ligando tipo delta 4.
AU2018253580A1 (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
AU2011270668A8 (en) CNS delivery of therapeutic agents
MX354776B (es) Enzimas de reemplazo lisosomal para usarse en el tratamiento de enfermedades de almacenamiento lisosomal.
NZ620326A (en) Cd37 immunotherapeutic combination therapies and uses thereof
JO3002B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
WO2014004993A3 (en) Methods of reducing ldl-p
PH12014502217A1 (en) Methods for improving diaphragm function
MX2010003884A (es) Anticuerpo dirigido a la proteina lecitina similar a inmunoglobulina de union a acido sialico-15 relacionado con osteoclastos.
AU2018205186B2 (en) Angiotensin in treating brain conditions
MY160979A (en) A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
WO2011140208A3 (en) Methods and compositions for diagnosing and treating autoimmune disorders
GB2477256A (en) Medicament and method of diagnosis
MX2011006725A (es) Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20.
MX347372B (es) Uso de metformina en combinacion con un activador de glucoquinasa y composiciones que comprenden metformina y un activador de glucoquinasa.
MX357169B (es) Biomarcadores de diabetes.
WO2012068463A3 (en) Methods of treating obesity by inhibiting nicotinamide n-methyl transferase (nnmt)
TR201900438T4 (tr) Prader-wıllı sendromunun tedavisinde kullanıma yönelik asillenmemiş girelin fragmentleri.
EP2566502A4 (en) METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION
MX2015015519A (es) Regulador de papalisina.
MY154376A (en) A transdermal fluid
MX2014006990A (es) Tratamiento para diabetes tipo i y tipo ii.
EP2550532A4 (en) METHOD FOR THE SUPPRESSION OF TUMORS, INCREASED WEIGHT LOSS AND / OR INCREASED INSULIN SENSITIVITY
MX2013011561A (es) Compuestos de benzodioxepina y benzodioxina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
MX2012004855A (es) Metodos para tratar enfermedad de parkinson.

Legal Events

Date Code Title Description
FG Grant or registration